CoChat

Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Angiogenesis is generally involved during the cancer development and hematogenous metastasis. Vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) are considered to have an important role in tumor-associated angiogenesis. However, the effects of simultaneously targeting on VEGF and EGFR on the growth and angiogenesis of colorectal cancer (CRC), and its underlying mechanisms remain unknown. METHODS: Immunohistochemical staining was used to detect the VEGF and EGFR expression in different CRC tissue specimens, and the correlation between VEGF/EGFR expression with the clinicopathologic features was analyzed. Cell counting kit‑8 (CCK-8) and transwell assays were used to assess the cellular proliferation and invasion of CRC cells after treated with anti-VEGF antibody and/or anti-EGFR antibody in vitro, respectively. Moreover, in vivo tumor formation was performed on nude mice model, and the tumor microvessel density (MVD) was determined by anti-CD34 staining in different groups. Finally, we evaluated the impact of anti-VEGF antibody and/or anti-EGFR antibody on the activation of downstream signaling effectors using western blot. RESULTS: VEGF and EGFR were upregulated in CRC tissues, and their expression levels were correlated with hepatic metastasis. Blockage on VEGF or EGFR alone could inhibit the cellular proliferation and metastasis while their combination could reach a good synergism in vitro. In addition, in vivo xenograft mice model demonstrated that the tumor formation and angiogenesis were strongly suppressed by combination treatment of anti-VEGF and anti-EGFR antibodies. Besides, the combination treatment significantly reduced the activation of AKT and ERK1/2, but barely affected the activation of c-Myc, NF-κB/p65 and IκBα in CRC cells tumors. Interestingly, anti-VEGF antibody or anti-EGFR antibody alone could attenuate the phosphorylation of STAT3 as compared with negative control group, whereas the combined application not further suppressed but at least partially restored the activation of STAT3 in vivo. CONCLUSIONS: Simultaneous targeting on VEGF and EGFR does show significant inhibition on CRC tumor growth and angiogenesis in mice model, and these effects are mainly attributed to suppression of the AKT and ERK signaling pathways.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-016-2834-8

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 VEGF and EGFR expression are significantly upregulated in liver-metastatic CRC tissues. a Results of VEGF staining were evaluated by the staining scores. b Results of EGFR staining were evaluated by the staining scores. c Immunohistochemistry analysis of VEGF and EGFR expression in different colorectal tissues. *P < 0.05
Fig. 1 VEGF and EGFR expression are significantly upregulated in liver-metastatic CRC tissues. a Results of VEGF staining were evaluated by the staining scores. b Results of EGFR staining were evaluated by the staining scores. c Immunohistochemistry analysis of VEGF and EGFR expression in different colorectal tissues. *P < 0.05CC BY · PubMed Central
Fig. 2 Expression of VEGF and EGFR in CRC cell lines. a Expression of VEGF in four human CRC cell lines was detected by qRT-PCR. b Expression of EGFR in four human CRC cell lines was detected by qRT-PCR. c Western blot analysis of VEGF and EGFR expression in different CRC cell lines
Fig. 2 Expression of VEGF and EGFR in CRC cell lines. a Expression of VEGF in four human CRC cell lines was detected by qRT-PCR. b Expression of EGFR in four human CRC cell lines was detected by qRT-PCR. c Western blot analysis of VEGF and EGFR expression in different CRC cell linesCC BY · PubMed Central
Fig. 3 Combined application of anti-VEGF and anti-EGFR antibodies suppresses the proliferation and invasion of CRC cells in vitro. a The proliferation rate of SW620 and LoVo cells were analyzed by CCK-8 assay in different groups. b Invasion assay of SW620 and LoVo cells in different groups. c Invasion of SW620 and LoVo cells were quantitatively analyzed in different groups. Columns are the average of three independent experiments ± SEM. *P < 0.05; **P < 0.01
Fig. 3 Combined application of anti-VEGF and anti-EGFR antibodies suppresses the proliferation and invasion of CRC cells in vitro. a The proliferation rate of SW620 and LoVo cells were analyzed by CCK-8 assay in different groups. b Invasion assay of SW620 and LoVo cells in different groups. c Invasion of SW620 and LoVo cells were quantitatively analyzed in different groups. Columns are the average of three independent experiments ± SEM. *P < 0.05; **P < 0.01CC BY · PubMed Central
Fig. 4 Suppression of CRC cells tumorigenicity by anti-VEGF and anti-EGFR antibodies in vivo. a Representative photographs of tumor formation in mice in response to SW620 cells. b Five weeks later, the tumors were resected and weighted. The weight analyzed with Student’s t-test. Data represent means ± SEM. *P < 0.05
Fig. 4 Suppression of CRC cells tumorigenicity by anti-VEGF and anti-EGFR antibodies in vivo. a Representative photographs of tumor formation in mice in response to SW620 cells. b Five weeks later, the tumors were resected and weighted. The weight analyzed with Student’s t-test. Data represent means ± SEM. *P < 0.05CC BY · PubMed Central
Fig. 5 Suppression of CRC cells tumor angiogenesis by anti-VEGF and anti-EGFR antibodies. a Representative photographs of anti-CD34 staining in SW620 cells tumors. b The numbers of positively CD34 stained cells in subcutaneous SW620 and LoVo cells tumors. The data are representative of at least three different experiments ± SEM. *P < 0.05
Fig. 5 Suppression of CRC cells tumor angiogenesis by anti-VEGF and anti-EGFR antibodies. a Representative photographs of anti-CD34 staining in SW620 cells tumors. b The numbers of positively CD34 stained cells in subcutaneous SW620 and LoVo cells tumors. The data are representative of at least three different experiments ± SEM. *P < 0.05CC BY · PubMed Central
Fig. 6 Combined application of anti-VEGF and anti-EGFR antibodies attenuates the activation of AKT and ERK, but not STAT3, c-Myc and NF-κB in vivo. a Western blot analysis was performed to determine the activation of AKT, ERK1/2 and STAT3 in different SW620 cells tumors. b Western blot assay of different LoVo cells tumors (one clone, a). c Western blot analysis was performed to determine the activation of c-Myc, NF-κB/p65 and IκBα in different SW620 cells tumors. d Western blot assay of different LoVo cells tumors (one clone, c)
Fig. 6 Combined application of anti-VEGF and anti-EGFR antibodies attenuates the activation of AKT and ERK, but not STAT3, c-Myc and NF-κB in vivo. a Western blot analysis was performed to determine the activation of AKT, ERK1/2 and STAT3 in different SW620 cells tumors. b Western blot assay of different LoVo cells tumors (one clone, a). c Western blot analysis was performed to determine the activation of c-Myc, NF-κB/p65 and IκBα in different SW620 cells tumors. d Western blot assay of different LoVo cells tumors (one clone, c)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 59 references

Cited by

See all 60

Metadata

Authors
Ding, C., Li, L., Yang, T., Fan, X., & Wu, G.
Affiliations
  • Southeast University (CN)
  • Zunyi Medical University (CN)
  • Zhongda Hospital Southeast University (CN)
Corresponding author
Wu, Guoqiu
Venue
BMC Cancer
Published
2016-10-12
Volume
16
Issue
1
Pages
791-791
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2530365028
Cited by
56
References
59
Citations by year
2026: 5 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 9 · 2021: 7 · 2020: 8 · 2019: 7 · 2018: 5 · 2017: 4 · 2016: 1
FWCI
2.94
Type
journal article
Language
en
Open access
Locations
  • BMC Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Natural Science Foundation of China (CN) (No. 30970809)
  • National Natural Science Foundation of China (NO. 81271636)
  • Natural Science Foundation of Jiangsu Province (No. BK2009274)
  • Special Fund of Clinical Medicine, Jiangsu Province, China (No. BL2012063)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
colorectal cancer, anti-VEGF antibody, anti-EGFR monoclonal antibody, combination therapy, tumor angiogenesis, Akt signaling, ERK signaling, STAT3, liver metastasis, tumor cell proliferation, tumor invasion, tumor microvessel density, c-Myc, NF-κB
MeSH terms
Adult, Aged, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Disease Models, Animal, Female, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Metastasis, Neovascularization, Pathologic, Colorectal Neoplasms, Signal Transduction, Apoptosis, Angiogenesis Inhibitors, Xenograft Model Antitumor Assays, Vascular Endothelial Growth Factor A, Cell Line, Tumor, Tumor Burden, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Proto-Oncogene Proteins c-akt, Mice, Neoplasm Grading, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. https://app.cochat.ai/papers/10.1186/s12885-016-2834-8
The paper
Ding, C., Li, L., Yang, T., Fan, X., & Wu, G. (2016). Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer. https://doi.org/10.1186/s12885-016-2834-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.